NO20054223L - Antistoffmolekyler som har spesifisitet for human IL-1beta - Google Patents
Antistoffmolekyler som har spesifisitet for human IL-1betaInfo
- Publication number
- NO20054223L NO20054223L NO20054223A NO20054223A NO20054223L NO 20054223 L NO20054223 L NO 20054223L NO 20054223 A NO20054223 A NO 20054223A NO 20054223 A NO20054223 A NO 20054223A NO 20054223 L NO20054223 L NO 20054223L
- Authority
- NO
- Norway
- Prior art keywords
- specificity
- beta
- human
- antibody molecules
- antibody molecule
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/245—IL-1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Abstract
Sammendrag Foreliggende oppfinnelse gjelder et antistoffmolekyl med spesifisitet for antigene deterininanter på IL-1ß, terapeutiske anvendelser av antistoffmolekylet og fremgangsmåter for fremstilling av antistoffmolekylet.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0303337.0A GB0303337D0 (en) | 2003-02-13 | 2003-02-13 | Biological products |
PCT/GB2004/000463 WO2004072116A2 (en) | 2003-02-13 | 2004-02-06 | ANTIBODY MOLECULES HAVING SPECIFICITY FOR HUMAN IL-1β |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20054223D0 NO20054223D0 (no) | 2005-09-12 |
NO20054223L true NO20054223L (no) | 2005-11-08 |
Family
ID=9952969
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20054223A NO20054223L (no) | 2003-02-13 | 2005-09-12 | Antistoffmolekyler som har spesifisitet for human IL-1beta |
Country Status (26)
Country | Link |
---|---|
US (2) | US7608694B2 (no) |
EP (2) | EP1597282B1 (no) |
JP (2) | JP4668896B2 (no) |
KR (1) | KR20050099509A (no) |
CN (1) | CN1745103A (no) |
AR (1) | AR043159A1 (no) |
AT (1) | ATE525397T1 (no) |
AU (1) | AU2004210776B2 (no) |
BR (1) | BRPI0407233A (no) |
CA (1) | CA2515474C (no) |
CL (1) | CL2004000259A1 (no) |
CY (1) | CY1112507T1 (no) |
DK (1) | DK1597282T3 (no) |
EA (1) | EA200501286A1 (no) |
EC (1) | ECSP056014A (no) |
ES (1) | ES2373953T3 (no) |
GB (1) | GB0303337D0 (no) |
IS (1) | IS8013A (no) |
MX (1) | MXPA05007392A (no) |
NO (1) | NO20054223L (no) |
PE (1) | PE20040947A1 (no) |
PL (1) | PL378412A1 (no) |
PT (1) | PT1597282E (no) |
SI (1) | SI1597282T1 (no) |
TW (1) | TW200505942A (no) |
WO (1) | WO2004072116A2 (no) |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0303337D0 (en) * | 2003-02-13 | 2003-03-19 | Celltech R&D Ltd | Biological products |
KR20070047327A (ko) | 2004-07-26 | 2007-05-04 | 비오겐 아이덱 엠에이 아이엔씨. | 항-cd154 항체 |
EP1851245B1 (en) * | 2005-01-26 | 2012-10-10 | Amgen Fremont Inc. | Antibodies against interleukin-1 beta |
MX348154B (es) | 2005-06-21 | 2017-05-30 | Xoma (Us) Llc | Anticuerpos de enlace a il-1-beta y fragmentos de los mismos. |
GB0513852D0 (en) * | 2005-07-06 | 2005-08-10 | Celltech R&D Ltd | Biological products |
CN102861332A (zh) * | 2005-10-26 | 2013-01-09 | 诺瓦提斯公司 | IL-1β化合物的新用途 |
BRPI0619595B8 (pt) | 2005-12-09 | 2022-12-13 | Ucb Pharma Sa | anticorpo neutralizante, sequência de dna isolada, vetor de clonagem ou expressão, célula hospedeira, processo para a produção de um anticorpo, composição farmacêutica, e, uso de um anticorpo neutralizante humanizado |
GB0612928D0 (en) * | 2006-06-29 | 2006-08-09 | Ucb Sa | Biological products |
GB0620729D0 (en) | 2006-10-18 | 2006-11-29 | Ucb Sa | Biological products |
JP5645409B2 (ja) | 2006-12-20 | 2014-12-24 | ゾーマ (ユーエス) リミテッド ライアビリティ カンパニー | IL−1β関連疾患の治療方法 |
MX2009010120A (es) | 2007-03-22 | 2009-10-19 | Ucb Pharma Sa | Proteinas de union, incluyendo anticuerpos, derivados de anticuerpo y fragmentos de anticuerpo, que se unen especificamente cd154 y sus usos. |
GB0717337D0 (en) | 2007-09-06 | 2007-10-17 | Ucb Pharma Sa | Method of treatment |
BRPI0820099A2 (pt) | 2007-12-07 | 2020-11-24 | Zymogenetics, Inc | anticorpo isolado ou fragmento de anticorpo, composição farmacêutica, e, uso de um anticorpo ou fragmento de anticorpo |
PL2391650T3 (pl) | 2007-12-20 | 2015-03-31 | Xoma Us Llc | Sposoby leczenia dny |
GB0807413D0 (en) | 2008-04-23 | 2008-05-28 | Ucb Pharma Sa | Biological products |
MX2010011761A (es) * | 2008-04-28 | 2010-11-30 | Kalobios Pharmaceuticals Inc | Anticuerpos para el factor que estimula la colonia del granulocito-macrofago. |
CA2735940A1 (en) | 2008-09-05 | 2010-03-11 | Xoma Technology Ltd. | Methods for treating or preventing il-1.beta. related diseases |
SG173620A1 (en) * | 2009-02-17 | 2011-09-29 | Ucb Pharma Sa | Antibody molecules having specificity for human ox40 |
GB0904214D0 (en) | 2009-03-11 | 2009-04-22 | Ucb Pharma Sa | Biological products |
BR112012006670B8 (pt) | 2009-09-24 | 2022-03-03 | Ucb Pharma Sa | Célula bacteriana gram-negativa recombinante, e, método para produzir uma proteína recombinante |
BR112012007365A2 (pt) * | 2009-10-15 | 2016-11-22 | Abbott Lab | proteínas de ligação à il-1 |
GB201000587D0 (en) | 2010-01-14 | 2010-03-03 | Ucb Pharma Sa | Bacterial hoist strain |
GB201000590D0 (en) | 2010-01-14 | 2010-03-03 | Ucb Pharma Sa | Bacterial host strain |
GB201000591D0 (en) | 2010-01-14 | 2010-03-03 | Ucb Pharma Sa | Bacterial hoist strain |
MX337586B (es) | 2010-05-07 | 2016-03-11 | Xoma Us Llc | Anticuerpos anti-interleucina-1beta para usarse en el tratamiento de condiciones relacionadas con interleucina-1beta. |
LT2571532T (lt) | 2010-05-14 | 2017-08-10 | Abbvie Inc. | Il-1 surišantys baltymai |
GB201012599D0 (en) | 2010-07-27 | 2010-09-08 | Ucb Pharma Sa | Process for purifying proteins |
US8465413B2 (en) | 2010-11-25 | 2013-06-18 | Coloplast A/S | Method of treating Peyronie's disease |
MA34907B1 (fr) | 2011-01-14 | 2014-02-01 | Ucb Pharma Sa | Molécules d'anticorps se liant à il-17a et il-17f |
ES2659155T3 (es) | 2011-07-13 | 2018-03-14 | Ucb Biopharma Sprl | Cepa hospedante bacteriana que expresa DSBC recombinante |
UA112203C2 (uk) | 2011-11-11 | 2016-08-10 | Юсб Фарма С.А. | Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини |
CN104144946A (zh) | 2011-12-19 | 2014-11-12 | 爱克索马美国有限责任公司 | 治疗痤疮的方法 |
PL2814843T3 (pl) | 2012-02-13 | 2020-11-16 | Agency For Science, Technology And Research | Ludzkie przeciwciała monoklonalne neutralizujące IL-β |
WO2013157102A1 (ja) * | 2012-04-18 | 2013-10-24 | 公立大学法人大阪市立大学 | ムチンサブタイプ5ac特異的ヒト化抗体およびその利用 |
WO2013157105A1 (ja) * | 2012-04-18 | 2013-10-24 | 公立大学法人大阪市立大学 | ムチンサブタイプ5ac特異的ヒト化抗体およびその利用 |
GB201208367D0 (en) | 2012-05-14 | 2012-06-27 | Ucb Pharma Sa | Biological product |
WO2014011955A2 (en) | 2012-07-12 | 2014-01-16 | Abbvie, Inc. | Il-1 binding proteins |
CN104341501B (zh) * | 2013-07-29 | 2019-08-30 | 上海睿智化学研究有限公司 | 抗IL-1β人源化单克隆抗体及其制备方法和应用 |
JP6397933B2 (ja) | 2014-01-20 | 2018-09-26 | ユーシービー バイオファルマ エスピーアールエル | 固体形態の医薬組成物の再構成のための方法 |
GB201501613D0 (en) | 2015-01-30 | 2015-03-18 | Ucb Biopharma Sprl | Treatment of autoimmune disorders with CD154 antibodies |
US9560393B2 (en) * | 2015-02-20 | 2017-01-31 | Disney Enterprises, Inc. | Media processing node |
CN106349388B (zh) * | 2015-07-17 | 2021-04-02 | 上海佳文英莉生物技术有限公司 | 一种促细胞程序性坏死抗体及其应用 |
WO2017072183A1 (en) | 2015-10-27 | 2017-05-04 | Ucb Biopharma Sprl | Methods of treatment using anti-il-17a/f antibodies |
GB201616596D0 (en) | 2016-09-29 | 2016-11-16 | Nascient Limited | Epitope and antibodies |
CN110818793A (zh) * | 2018-08-14 | 2020-02-21 | 中山康方生物医药有限公司 | 抗IL-1β的抗体、其药物组合物及其用途 |
JP7256266B2 (ja) * | 2018-11-07 | 2023-04-11 | 沢達生物医薬有限公司 | ヒトIL-1βに結合する抗体、その調製方法及び用途 |
GB201919062D0 (en) | 2019-12-20 | 2020-02-05 | Ucb Biopharma Sprl | Antibody |
CN116802211A (zh) | 2020-12-07 | 2023-09-22 | Ucb生物制药有限责任公司 | 针对白介素-22的抗体 |
MX2023006650A (es) | 2020-12-07 | 2023-06-21 | UCB Biopharma SRL | Anticuerpos multiespecificos y combinaciones de anticuerpos. |
KR20240004694A (ko) | 2021-05-03 | 2024-01-11 | 유씨비 바이오파마 에스알엘 | 항체 |
GB202111905D0 (en) | 2021-08-19 | 2021-10-06 | UCB Biopharma SRL | Antibodies |
CN113855807A (zh) * | 2021-10-25 | 2021-12-31 | 孙良丹 | 一种试剂在制备治疗/抑制银屑病药物中的应用 |
CN114524875B (zh) * | 2021-11-11 | 2023-07-25 | 江苏莱森生物科技研究院有限公司 | 偶联IL-1β单克隆抗体的纳米硅球及应用 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB129105A (en) | 1918-07-02 | 1919-07-02 | Alfred George Hubble | Improvements in and connected with Closing Means for Milk Churns, Containers and Vessels. |
EP0569687B1 (en) * | 1984-05-18 | 2002-08-21 | New England Medical Center Hospitals, Inc. | Human IL-1 cDNA sequences encoding biologically-active human IL-1 proteins |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
DK336987D0 (da) | 1987-07-01 | 1987-07-01 | Novo Industri As | Immobiliseringsmetode |
US4935343A (en) * | 1986-08-08 | 1990-06-19 | Syntex (U.S.A.) Inc. | Monoclonal antibodies for interleukin-1β |
US5474899A (en) * | 1987-05-13 | 1995-12-12 | Cistron Biotechnology, Inc. | Selective immunoassay for IL-1 β |
GB8719042D0 (en) | 1987-08-12 | 1987-09-16 | Parker D | Conjugate compounds |
GB8907617D0 (en) | 1989-04-05 | 1989-05-17 | Celltech Ltd | Drug delivery system |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
GB9112536D0 (en) | 1991-06-11 | 1991-07-31 | Celltech Ltd | Chemical compounds |
GB9120467D0 (en) | 1991-09-26 | 1991-11-06 | Celltech Ltd | Anti-hmfg antibodies and process for their production |
WO1995001997A1 (en) | 1993-07-09 | 1995-01-19 | Smithkline Beecham Corporation | RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN |
DK0813423T3 (da) | 1995-01-23 | 2002-07-22 | Xenotech Inc | Præparat til forebyggelse af osteolysis og metastase |
JPH09183799A (ja) * | 1995-11-06 | 1997-07-15 | Merck Patent Gmbh | ヒト化モノクローナル抗体 |
US5980898A (en) | 1996-11-14 | 1999-11-09 | The United States Of America As Represented By The U.S. Army Medical Research & Material Command | Adjuvant for transcutaneous immunization |
GB9625640D0 (en) | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
GB9720054D0 (en) * | 1997-09-19 | 1997-11-19 | Celltech Therapeutics Ltd | Biological products |
GB0001448D0 (en) | 2000-01-21 | 2000-03-08 | Novartis Ag | Organic compounds |
GB0013810D0 (en) * | 2000-06-06 | 2000-07-26 | Celltech Chiroscience Ltd | Biological products |
GB0020685D0 (en) | 2000-08-22 | 2000-10-11 | Novartis Ag | Organic compounds |
US20030026806A1 (en) * | 2000-10-27 | 2003-02-06 | Amgen Inc. | Antibodies and other selective IL-1 binding agents that allow binding to IL-1 receptor but not activation thereof |
US20050075488A1 (en) | 2001-07-26 | 2005-04-07 | Bright Stuart Willis | Interleukin-1 beta antibodies |
GB0303337D0 (en) * | 2003-02-13 | 2003-03-19 | Celltech R&D Ltd | Biological products |
-
2003
- 2003-02-13 GB GBGB0303337.0A patent/GB0303337D0/en not_active Ceased
-
2004
- 2004-02-06 WO PCT/GB2004/000463 patent/WO2004072116A2/en active Application Filing
- 2004-02-06 PL PL378412A patent/PL378412A1/pl unknown
- 2004-02-06 JP JP2006502246A patent/JP4668896B2/ja not_active Expired - Fee Related
- 2004-02-06 PT PT04708808T patent/PT1597282E/pt unknown
- 2004-02-06 AU AU2004210776A patent/AU2004210776B2/en not_active Ceased
- 2004-02-06 US US10/544,911 patent/US7608694B2/en not_active Expired - Fee Related
- 2004-02-06 MX MXPA05007392A patent/MXPA05007392A/es not_active Application Discontinuation
- 2004-02-06 AT AT04708808T patent/ATE525397T1/de active
- 2004-02-06 BR BR0407233-2A patent/BRPI0407233A/pt not_active Application Discontinuation
- 2004-02-06 CA CA2515474A patent/CA2515474C/en not_active Expired - Fee Related
- 2004-02-06 EA EA200501286A patent/EA200501286A1/ru unknown
- 2004-02-06 CN CNA2004800033654A patent/CN1745103A/zh active Pending
- 2004-02-06 DK DK04708808.3T patent/DK1597282T3/da active
- 2004-02-06 EP EP04708808A patent/EP1597282B1/en not_active Expired - Lifetime
- 2004-02-06 SI SI200431797T patent/SI1597282T1/sl unknown
- 2004-02-06 ES ES04708808T patent/ES2373953T3/es not_active Expired - Lifetime
- 2004-02-06 KR KR1020057013813A patent/KR20050099509A/ko not_active Application Discontinuation
- 2004-02-06 EP EP10182246A patent/EP2287193A1/en not_active Withdrawn
- 2004-02-09 PE PE2004000142A patent/PE20040947A1/es not_active Application Discontinuation
- 2004-02-12 CL CL200400259A patent/CL2004000259A1/es unknown
- 2004-02-12 AR ARP040100431A patent/AR043159A1/es unknown
- 2004-02-12 TW TW093103340A patent/TW200505942A/zh unknown
-
2005
- 2005-09-07 IS IS8013A patent/IS8013A/is unknown
- 2005-09-12 NO NO20054223A patent/NO20054223L/no unknown
- 2005-09-13 EC EC2005006014A patent/ECSP056014A/es unknown
-
2009
- 2009-09-29 US US12/569,700 patent/US8465744B2/en not_active Expired - Fee Related
-
2010
- 2010-06-04 JP JP2010128372A patent/JP2010246553A/ja active Pending
-
2011
- 2011-12-21 CY CY20111101274T patent/CY1112507T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20054223L (no) | Antistoffmolekyler som har spesifisitet for human IL-1beta | |
EA200801427A1 (ru) | Молекулы антитела со специфической активностью в отношении интерлейкина-6 (ил-6) человека | |
TW200621801A (en) | Antibody molecules having specificity for human IL-17 | |
EA200900492A1 (ru) | Молекулы антител, которые связываются с il-17a и il-17f | |
ATE364618T1 (de) | Antikörper gegen das muc18-antigen | |
NO20054371L (no) | Somatostatin-dopamin kimaere analoger | |
ME00425B (me) | Liječenje sa anti-vegf antitijelima | |
NO20065560L (no) | Anvendelse av IL-17-uttrykking for a forutsi hudinflammasjon, fremgangsmater for behandling. | |
EA201100694A1 (ru) | Антитело к cd38 человека и его применение | |
CY1112277T1 (el) | ΑΝΘΡΩΠΟΠΟΙΗΜΕΝΟΙ ΑΝΤΑΓΩΝΙΣΤΕΣ ΑΝΤΙ-β7 ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΩΝ | |
ATE553778T1 (de) | Für humanes hepcidin spezifische antikörper | |
NO20065859L (no) | Bruk av IL-17 behandlingen av fertilitetsrelaterte lidelser | |
NO20055450L (no) | Kombinasjon av et analeptisk modafinili og en antidepressiv forbindelse for behandling av depresjon | |
ECSP055659A (es) | Derivados de cicloalquilamina antidepresiva de benzodioxanos fusionados con heterociclos | |
EA200400399A1 (ru) | Способы лечения легочных заболеваний | |
ATE455789T1 (de) | Substituierte nonadepsipeptide | |
NO20061425L (no) | Kombinasjonen av en serotonin-reopptaksinbibitor og loxapin | |
DK1412503T3 (da) | Et fusionsprotein | |
ATE410415T1 (de) | Neue verbindungen | |
CY1115868T1 (el) | Μορια αντισωματων που εχουν ειδικο χαρακτηρα για το ανθρωπινο il-6 | |
EA200401523A1 (ru) | Способы применения и композиции для диагностики и лечения инфекционного заболевания | |
DE60327896D1 (de) | Einschlusskörper als antigene für die orale impfung von tieren gegen csfv | |
EA200701031A1 (ru) | Молекулы, способствующие гематопоэзу | |
UA2986U (uk) | Спосіб лікування розсіяного склерозу | |
TH71073A (th) | แอนติบอดีโมเลกุลที่มีความจำเพาะสำหรับ il-1(เบตา) ของคน |